

HOUSE No. 1804

The Commonwealth of Massachusetts

PRESENTED BY:

Shaunna O'Connell and Patricia D. Jehlen

To the Honorable Senate and House of Representatives of the Commonwealth of Massachusetts in General Court assembled:

The undersigned legislators and/or citizens respectfully petition for the adoption of the accompanying bill:

An Act relative to the overuse of psychoactive drugs on the elderly.

PETITION OF:

NAME:	DISTRICT/ADDRESS:
<i>Shaunna O'Connell</i>	<i>3rd Bristol</i>
<i>Nancy Sylvester</i>	<i>13 Pinckney Street</i> <i>□ Taunton, MA 02780</i>
<i>Cory Atkins</i>	<i>14th Middlesex</i>
<i>Matthew A. Beaton</i>	<i>11th Worcester</i>
<i>Angelo L. D'Emilia</i>	<i>8th Plymouth</i>
<i>Jonathan Hecht</i>	<i>29th Middlesex</i>
<i>Paul R. Heroux</i>	<i>2nd Bristol</i>
<i>Patricia D. Jehlen</i>	<i>Second Middlesex</i>
<i>Paul McMurtry</i>	<i>11th Norfolk</i>
<i>Keiko M. Orrall</i>	<i>12th Bristol</i>
<i>Elizabeth A. Poirier</i>	<i>14th Bristol</i>
<i>Denise Provost</i>	<i>27th Middlesex</i>
<i>Todd M. Smola</i>	<i>1st Hampden</i>

HOUSE No. 1804

By Mrs. O'Connell of Taunton and Senator Jehlen, a joint petition (accompanied by bill, House, No. 1804) of Shaunna O'Connell and others for legislation to further regulate the use of psychoactive drugs on distressed patients. Mental Health and Substance Abuse.

The Commonwealth of Massachusetts

In the Year Two Thousand Thirteen

An Act relative to the overuse of psychoactive drugs on the elderly.

Be it enacted by the Senate and House of Representatives in General Court assembled, and by the authority of the same, as follows:

1 Chapter 111 of the General Laws, as appearing in the 2010 Official Edition, is hereby
2 amended by inserting after section 72AA the following section:—

3 Section 72BB. (a) As used in this section, the following terms shall have the following
4 meanings:

5 “Behavioral Intervention”, individualized non-pharmacological approaches that are
6 provided as part of a supportive physical and psychosocial environment, and are directed toward
7 preventing, relieving, and/or accommodating a patient’s distressed behavior.

8 “Boxed Warning”, a warning, as determined by the Food and Drug Administration that
9 appears on a prescription drug’s label and is designed to call attention to serious or life-
10 threatening risks.

11 “Facility”, a facility for the delivery of health services and includes: a community health
12 center, public health center, outpatient medical facility, or community mental health center; a
13 hospital, State mental hospital, facility for long-term care, or rehabilitation facility.

14 “Incapacitated Person”, an individual who for reasons other than advanced age or
15 minority, has a clinically diagnosed condition that results in an inability to receive and evaluate
16 information or make or communicate decisions to such an extent that the individual lacks the
17 ability to meet essential requirements for physical health, safety, or self-care, even with
18 appropriate technological assistance.

19 “Legal Representative”, for any patient adjudged incompetent under the laws of the
20 Commonwealth, the person duly appointed by a court of competent jurisdiction to act on the
21 patient’s behalf, and, for any patient who has not been adjudged incompetent by a state court,
22 any legal-surrogate designated in accordance with state law.

23 “Psychoactive Medication”, any medication used for managing behavior, sleep
24 disorders, stabilizing mood, or treating psychiatric disorders.

25 (b) A physician, an advanced practice nurse prescriber certified under 244 CMR 4.00, or
26 a physician assistant licensed under 263 CMR 3.05, who prescribes a psychoactive medication to
27 a patient, shall notify the facility if the prescribed medication has a boxed warning under 21 CFR
28 201.57.

29 (c) Except as provided in subsection (h) or subsection (i), before administering a
30 psychoactive medication to a patient, a facility shall obtain written informed consent from the
31 patient or, if the patient is incapacitated, a legal representative of the patient, on a form provided
32 by the department under subsection (e) or on a form that contains the same information as the
33 form under subsection (e).

34 (d) Prior to increasing the dosage of a psychoactive medication, a facility shall obtain oral
35 consent from the patient or, if the patient is incapacitated, a legal representative of the patient.

36 (e) The department shall make available on its web site drug-specific forms for obtaining
37 informed consent for the administration of psychoactive medication that contain all of the
38 following:

39 (1) A space for a description of the benefits of the proposed treatment.

40 (2) A space for a description of the way the psychoactive medication shall be
41 administered, including but not limited to, how long and how often the drug shall be used, and
42 how and by whom side effects shall be monitored.

43 (3) A description, using the most recently issued information from the Food and Drug
44 Administration, of the side effects or risks of side effects of the medication and any warnings
45 about the medication. The description shall include, but not limited to, boxed warnings, potential
46 drug interactions and information relative to FDA approval.

47 (4) A space for a description of any alternative treatments, including but not limited to,
48 behavior interventions and medications.

49 (5) A space for a description of treatment modes and medications that have been
50 previously administered.

51 (6) A space for indicating the period for which the informed consent is effective, which
52 shall be no longer than 3 months from the time the consent is given.

53 (7) A statement that the patient or a legal representative of the patient may withdraw
54 informed consent, in writing, at any time.

55 (8) A statement that patient or a legal representative of the patient has the right to accept
56 or refuse the psychoactive medication at any time.

57 (9) A space for a description of the probable consequences of not receiving the
58 medication and a statement that the withdrawal or refusal of treatment shall not relieve a facility
59 of its duty to provide reasonable treatment to the patient.

60 (10) A declaration that the patient or the legal representative of the patient has been
61 provided with specific, complete, and accurate information, and sufficient time to study the
62 information or to seek additional information concerning the medication.

63 (11) A space for the signature of the patient or the legal representative of the patient.

64 (f) Upon request, the facility shall give the patient, or a legal representative of the patient,
65 a copy of the completed informed consent form.

66

67 (g) Unless consent is withdrawn sooner, written informed consent obtained under this
68 subsection is valid for the period specified on the

69 informed consent form but not for longer than 3 months from the date the patient, or a
70 legal representative of the patient, signed the form.

71 (h) A patient, or a legal representative of the patient, has the right to revoke consent for
72 any reason, at any time.

73 (i) A facility is not required to obtain written informed consent before administering a
74 psychoactive medication to a patient under subsection (c) if all of the following apply:

75 (1) There is an emergency in which a patient is at imminent and serious risk of
76 physical or emotional harm or the patient puts others at imminent and serious risk of physical
77 harm, and in which time or distance precludes obtaining written informed consent before
78 administering psychoactive medication.

79 (2) A physician has determined that the patient or others will be harmed if the
80 psychoactive medication is not administered before written informed consent is obtained.

81 (j) If subsection (i) applies, the facility shall obtain oral consent from the patient or, if the
82 patient is incapacitated, a legal representative of the patient, before administering the
83 psychoactive medication, except as provided in subsection (k). The oral consent and
84 documentation as to why the drug was prescribed, signed by the patient or legal representative of

85 the patient, shall be entered in the patient's medical record. The oral consent shall be valid for a
86 maximum period of 2 days, after which time the facility may not continue to administer the
87 psychoactive medication unless it has obtained written informed consent under subsection (c).

88 (k) If subsection (i) applies, the patient is incapacitated, and the facility has made a good
89 faith effort to obtain oral consent, under subsection (j), of a legal representative of the patient but
90 has been unable to contact such a person, the facility may administer the psychoactive
91 medication to the patient for up to 24 hours before obtaining consent under subsection (c) or
92 subsection (i).